GH Earnings & Financial Statements
Guardant Health, Inc.
$162.99
+$0.91(+0.56%)
53
Overall
40
Value
41
Tech
78
Quality
Market Cap
$21.87B
Volume
1.28M
52W Range
$61.00 - $191.05
Target Price
$204.00
GH earnings and financial statements: Guardant Health, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
GH Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $982.02M | $739.02M | $563.95M | $449.54M | $373.65M |
| Cost of revenue | $349.01M | $289.80M | $227.05M | $156.32M | $122.91M |
| Operating income | -$437.25M | -$443.59M | -$564.73M | -$544.38M | -$411.00M |
| EBITDA | -$373.91M | -$390.12M | -$430.73M | -$612.34M | -$359.62M |
| Net income | -$416.28M | -$436.37M | -$479.45M | -$654.59M | -$405.67M |
| EPS (diluted) | $-3.32 | $-3.56 | $-4.28 | $-6.41 | $-4.00 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $2.01B | $1.49B | $1.79B | $1.61B | $2.20B |
| Total liabilities | $2.11B | $1.63B | $1.63B | $1.55B | $1.56B |
| Shareholders’ equity | -$99.31M | -$139.65M | $158.68M | $60.18M | $645.00M |
| Cash and equivalents | $378.20M | $525.54M | $1.13B | $141.65M | $492.20M |
| Long-term debt | $1.68B | $1.31B | $1.33B | $1.35B | $1.36B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$184.76M | -$239.86M | -$324.98M | -$309.46M | -$209.02M |
| Capital expenditure | -$48.31M | -$35.09M | -$20.49M | -$77.46M | -$75.03M |
| Free cash flow | -$233.07M | -$274.94M | -$345.46M | -$386.92M | -$284.05M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GH | $162.99 | +0.6% | 1.28M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |